You can buy or sell ATNM and other stocks, options, ETFs, and crypto commission-free!
Actinium Pharmaceuticals, Inc, also called Actinium Pharmaceuticals, is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Read More Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Yahoo FinanceMar 7
What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?
A look at the shareholders of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership. With a market capitalization of US$68m, Actinium Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownersh...
Stock Price, News, & Analysis for Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatm...
-$0.06 per share
-$0.05 per share